Tumor-agnostic inhibitors in oncology: A new phase for precision medicine

Mu Chun Li, Hsing Pang Hsieh

Research output: Contribution to journalArticlepeer-review

Abstract

The study of precision medicine is flourishing in recent decades. Tumor-agnostic therapy is one of the targeted therapies, which can treat the malignant cells regardless of where they grow. Herein we reviewed currently the U.S. FDA-approved tumor-agnostic therapies: one monoclonal antibody as a PD-1 inhibitor called pembrolizumab and four small-molecule kinase inhibitors, larotrectinib, entrectinib, selpercatinib, and pralsetinib. We also summarized the reported synthetic routes toward three drugs and some developing candidates under clinical trials as tumor-agnostic therapy.

Original languageEnglish
Pages (from-to)2216-2224
Number of pages9
JournalJournal of the Chinese Chemical Society
Volume67
Issue number12
DOIs
Publication statusPublished - 2020 Dec

All Science Journal Classification (ASJC) codes

  • Chemistry(all)

Fingerprint Dive into the research topics of 'Tumor-agnostic inhibitors in oncology: A new phase for precision medicine'. Together they form a unique fingerprint.

Cite this